MIP Discovery has announced its rebranding to Tozaro, marking its transition to a leading innovator in the cell and gene therapy (CGT) bioprocessing sector. This change comes in the wake of significant growth, including a strategic refocusing on enhancing downstream processing in the CGT industry and the successful completion of a £7M Series A funding round in February. The rebrand underscores Tozaro’s commitment to advancing CGT bioprocessing through its cutting-edge smart polymer technology.
Tozaro’s smart polymers are meticulously designed using computational chemistry to create novel affinity solutions. These polymers push the boundaries of current biological reagents by targeting unique surface epitopes on whole viruses for synthetic affinity reagents. A library of over 600 monomers is screened to identify those with optimal characteristics for new polymer development. This process allows precise control over features such as virus affinity, tailoring the polymers for specific applications in analytics and purification. The scalability and safety of these non-biological affinity reagents offer innovative solutions for viral vector purification and analytical tools.
Dr. Mike Evans, Chair of the Board at Tozaro, commented, “The promise of cell and gene therapies is often limited by the high cost and inefficiency of current production methods. Tozaro’s novel approach to creating reagents for viral vector manufacturing has the potential to transform this landscape.” He added that the rebrand to Tozaro reflects the company’s dedication to growth and its focus on developing solutions that will facilitate the widespread adoption of next-generation therapies.
Guy Leaver, Interim CEO of Tozaro, noted, “We’ve already seen promising results with our initial wave of lentivirus smart polymers designed for analytics and capture chromatography. We are enthusiastic about continuing this progress as we move forward and expand our portfolio under our new identity, Tozaro.
